Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Methotrexate 5Peripheral Blood Stem Cell Transplantation 4Cyclosporine 4Busulfan 4Cyclophosphamide 3Azacitidine 3ruxolitinib 2fludarabine phosphate 2Tacrolimus 2Mycophenolic Acid 2Injections 2Filgrastim 2Decitabine 2Alemtuzumab 2venetoclax 1tagraxofusp 1posaconazole 1gilteritinib 1flt3 ligand protein 1ethanolamine oleate 1axatilimab 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thrombopoietin 1Sulfamethoxazole 1Stem Cell Factor 1Specimen Handling 1Sodium Chloride 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myelodysplastic-Myeloproliferative Diseases × posaconazole × Clear all
NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

BeOne Medicines

Phase 1/2 Recruiting
260 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡